ST Activators
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187, a calcium ionophore, indirectly activates ST. By facilitating calcium influx, it modulates calcium-dependent signaling pathways, influencing ST function. A23187's indirect activation of ST reveals the significance of calcium dynamics in regulating ST activity, providing a pharmacological tool to explore ST-related pathways in the context of altered intracellular calcium levels. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly activates ST. By inhibiting PI3K, it modulates ST-mediated signaling and cellular functions. LY294002's indirect activation of ST highlights the dependence of ST on PI3K signaling dynamics, providing a pharmacological approach to investigate ST-related pathways and their potential impact on cellular functions influenced by PI3K pathway activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly activates ST. By inhibiting the p38 MAPK pathway, it influences ST-mediated signaling and cellular functions. SB203580's indirect activation of ST reveals the dependence of ST on p38 MAPK signaling dynamics, providing a pharmacological tool to explore ST-related pathways in the context of altered p38 MAPK pathway activity. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
2-APB, an IP3 receptor inhibitor, indirectly activates ST. By inhibiting IP3 receptor-mediated calcium release, it influences ST-mediated signaling pathways. 2-APB's indirect activation of ST sheds light on the interplay between calcium dynamics and ST function, offering a chemical tool to explore and modulate ST-related pathways in the context of altered IP3 receptor activity. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $156.00 $612.00 | 27 | |
Calmidazolium, a calmodulin antagonist, indirectly activates ST. By disrupting calmodulin-dependent signaling, it modulates ST function. Calmidazolium's indirect activation of ST underscores the role of calmodulin in controlling ST activity, providing a pharmacological tool to explore ST-related pathways and their potential impact on cellular functions influenced by calmodulin signaling dynamics. | ||||||
Hesperadin | 422513-13-1 | sc-490384 | 10 mg | $304.00 | ||
Hesperadin, an Aurora kinase inhibitor, indirectly activates ST. By inhibiting Aurora kinase, it modulates ST-mediated signaling and cellular functions. Hesperadin's indirect activation of ST highlights the regulatory role of Aurora kinase in controlling ST activity, providing a pharmacological tool to explore ST-related pathways and their potential impact on cellular functions influenced by Aurora kinase signaling dynamics. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM 336372, a MEK1/2 inhibitor, indirectly activates ST. By inhibiting the MAPK pathway, it influences ST-mediated signaling and cellular functions. ZM 336372's indirect activation of ST reveals the dependence of ST on MAPK signaling dynamics, providing a pharmacological tool to explore ST-related pathways and their potential impact on cellular functions influenced by MAPK pathway activity. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7, a myosin light chain kinase inhibitor, indirectly activates ST. By inhibiting myosin light chain kinase, it modulates ST-mediated signaling and cellular functions. ML-7's indirect activation of ST highlights the regulatory role of myosin light chain kinase in controlling ST activity, providing a pharmacological approach to investigate ST-related pathways and their potential impact on cellular functions influenced by myosin light chain kinase signaling dynamics. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, indirectly activates ST. By inhibiting NF-κB signaling, it modulates ST-mediated signaling and cellular functions. BAY 11-7082's indirect activation of ST reveals the dependence of ST on NF-κB signaling dynamics, providing a pharmacological tool to explore ST-related pathways and their potential impact on cellular functions influenced by NF-κB pathway activity. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $182.00 | 25 | |
KN-93, a CaMKII inhibitor, indirectly activates ST. By inhibiting CaMKII, it modulates ST-mediated signaling and cellular functions. KN-93's indirect activation of ST highlights the regulatory role of CaMKII in controlling ST activity, providing a pharmacological approach to investigate ST-related pathways and their potential impact on cellular functions influenced by CaMKII signaling dynamics. | ||||||